Sirnaomics and China Partner File to Begin China Trials of siRNA Drug

Sirnaomics, a US-China biopharma, together with its partner Guangzhou Xiangxue Pharma, have filed with the CFDA to begin human clinical trials of STP705, an anti-fibrosis small interfering RNA (siRNA) drug. The trial, which will be conducted simultaneously in the US and China, will test whether STP705 prevents and treats human skin hypertrophic scars. Sirnaomics said STP705 is the first siRNA product to file a China Class 1.1 IND, a class reserved for novel drugs not previously approved anywhere in the world. More details.... Stock Symbol: (SHE: 300147) Share this with colleagues: // //